Journals / Harran Üniversitesi Tıp Fakültesi Dergisi / 2020 / Cilt: 17 - Sayı: 3

Assessment of Mean Platelet Volume in Acromegaly And Its Relation With The Treatment

Akromegalide Ortalama Trombosit Volümünün Değerlendirilmesi ve Tedavi ile İlişkisi

Pages
355–359
Publication Date
2020-12-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients who achieved disease control with medical therapy after failure of surgical intervention demonstrated MPV values similar to those reported in patients cured with, even after two years from surgery (p=0,001).Conclusions: Our findings suggested that MPV would be a beneficial marker for atherosclerosis and inflammation in patients with acromegaly.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Mean platelet volume (MPV) is an independent risk factor of atherosclerosis and thrombotic events.
📊
Key Findings & Data:A total of 80 patients treated at our clinic with the diagnosis of acromegaly age- and gender-matched nonacromegalic controls were reviewed retrospectively.
💡
Conclusion & Impact:Patients who achieved disease control with medical therapy after failure of surgical intervention demonstrated MPV values similar to those reported in patients cured with, even after two years from surgery (p=0,001).Conclusions: Our findings suggested that MPV would be a beneficial marker for atherosclerosis and inflammation in patients with acromegaly.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Acromegaly · Atherosclerosis · İnflammation

Abstract

Background: Mean platelet volume (MPV) is an independent risk factor of atherosclerosis and thrombotic events. We aimed this study evaluates the levels of MPV in acromegalic patients and its relationship with treatment.Materials and Methods: In this study, we examined the levels of MPV in acromegalic patients before and after treatment and also at two years of remission. The results were also compared with a control group. A total of 80 patients treated at our clinic with the diagnosis of acromegaly age- and gender-matched nonacromegalic controls were reviewed retrospectively. Preoperative and postoperative MPV values as well as MPV values two years after controlling disease in patients with medical treatment were compared.Results: MPV values were significantly higher in both the diabetic and non-diabetic acromegaly patients compared with the control subjects (p=0,02). Postoperative MPV values were significantly reduced compared to preoperative values in patients cured after surgery (p=0,001). Patients who achieved disease control with medical therapy after failure of surgical intervention demonstrated MPV values similar to those reported in patients cured with, even after two years from surgery (p=0,001).Conclusions: Our findings suggested that MPV would be a beneficial marker for atherosclerosis and inflammation in patients with acromegaly.

Özet

Amaç: Ortalama trombosit volümü (MPV) ateroskleroz ve trombotik olaylar için bağımsız bir risk faktörüdür. Çalışmamızda akromegalik hastalarda MPV düzeyini ve tedavi ile ilişkisini değerlendirmeyi amaçladık.Materyal ve Metod: Çalışmamızda akromegali hastalarında tedavi öncesi, tedavi sonrası ve remisyondan 2 yıl sonraki MPV düzeylerini değerlendirdik. Ayrıca sonuçları kontrol grubu ile karşılaştırdık. Kliniğimizde takipli 80 akromegali hastası yaş ve cinsiyet açısından benzer kontrol grubu ile retrospektif olarak kıyaslandı. Preoperatif ve postoperatif MPV değerleri ile medikal tedavi alan hastalarda hastalık kontrolünden iki yıl sonraki MPV değerleri karşılaştırıldı.Bulgular: Diyabetik ve non-diyabetik akromegali hastalarında MPV düzeyi kontrol grubuna göre anlamlı oranda yüksekti (p=0,02). Postoperatif kür sağlananlarda postoperatif MPV preoperatif MPV’ye göre anlamlı oranda düşüktü (p=0,001). Cerrahi tedavi başarısızlığından sonra medikal tedavi ile hastalık kontrolü sağlananlarda MPV düzeyi cerrahi ile kür sağlananlarla ameliyattan iki yıl sonra bile benzerdi (p=0,001).Sonuç: Bulgularımız, MPV'nin akromegali hastalarında ateroskleroz ve inflamasyon için yararlı bir belirteç olabileceğini düşündürmektedir.Anahtar kelimeler: Akromegali, Ateroskleroz, İnflamasyon, Ortalama trombosit volümü

🔖

Cite This Article

AKYAY, Ö. Z., SELEK, A., BATMAN, A., ÇETİNASLAN, B., CANTÜRK, Z., TARKUN, İ. (2020). Assessment of Mean Platelet Volume in Acromegaly And Its Relation With The Treatment. Harran Üniversitesi Tıp Fakültesi Dergisi, Cilt: 17 - Sayı: 3, 355–359. https://ajindex.com/articles/82146

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract. 2011; 17:1-44
  2. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lambert S, F. Casanueva, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148
  3. Wıllıam L, McGuffin WL, Phıllıp G, Ronald K, Wıllıam CR, Peter LF. Acromegaly and cardiovascular disorders: A prospective study. Ann Intern Med 1974;81:11–18 4. Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone E, Gargiulo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000; 85:193-199
  4. Sowers JR, Standley PR, Ram JL, Jacober S, Simpson L, Rose K. Hyperinsulinemia, insulin resistance and hyperglycemia: contributing factors in the pathogenesis of hypertension and atherosclerosis. Am J Hyperten 1993; 6:260-270
  5. Sherlock M, Ayuk J, Tomlinson JW, Toogod AA, Aragon-Alason A, Sheppard MC, et al. Mortality in patients with pituitary disease. Endocr Rev 2010; 31:301-342
  6. Kartal I, Oflaz H, Pamukcu B, Meriç M, Aral F, Özbey N, et al. Investigation of early atherosclerotic changes in acromegalic patients. Int J Clin Pract 2010; 64:39-44
  7. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des 2011;17:47-58
  8. Are´valo-Lorido JC, Carretero-Go´mez J, Villar-Vaca P. Mean platelet volume predicting carotid atherosclerosis in atherothrombotic ischemic stroke. Ir J Med Sci 2012;181:179-183
  9. Bath PM, Butterworth RJ. Palatelet size:measurement, phisology and vascular disease. Blood Coagul Fibrinolysis 1996; 7:157-161
  10. Sewell R, Ibbotson RM, Phillips R, Carson P. High mean platelet volume after myocardial infarction: is it due to consumption of small platelets? Br Med J(Clin Res Ed) 1984;289:1576–1578
  11. Elsenberg EH, van Werkum JW, van de Wall RM, Zomer AC, Bouman HJ, Verheugt FW, et al. The influence of clinical charasteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb and Haemost 2009; 102:719-727
  12. Kosus N, Kosus A, Turhan N. Mean platelet volume as a marker of future cardiovascular disease risk in pregnant women with impaired f